Anthera Pharmaceuticals Inc
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clini… Read more
Anthera Pharmaceuticals Inc (ANTH) - Total Liabilities
Latest total liabilities as of March 2018: $3.35 Million USD
Based on the latest financial reports, Anthera Pharmaceuticals Inc (ANTH) has total liabilities worth $3.35 Million USD as of March 2018.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Anthera Pharmaceuticals Inc - Total Liabilities Trend (2007–2017)
This chart illustrates how Anthera Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Anthera Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Anthera Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Brookside Energy Limited
PINK:RDFED
|
USA | $11.68 Million |
|
Gatron Industries Ltd
KAR:GATI
|
Pakistan | PKRs27.05 Billion |
|
Relevant Gold Corp
PINK:RGCCF
|
USA | $1.12 Million |
|
Blockchain Coinvestors Acquisition Corp. I Warrant
NASDAQ:BCSAW
|
USA | $16.90 Million |
|
Naos Emerging Opportunities Company Ltd
AU:NCC
|
Australia | AU$23.36 Million |
Liability Composition Analysis (2007–2017)
This chart breaks down Anthera Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.61 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Anthera Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Anthera Pharmaceuticals Inc (2007–2017)
The table below shows the annual total liabilities of Anthera Pharmaceuticals Inc from 2007 to 2017.
| Year | Total Liabilities | Change |
|---|---|---|
| 2017-12-31 | $9.17 Million | -16.66% |
| 2016-12-31 | $11.00 Million | +29.91% |
| 2015-12-31 | $8.47 Million | +47.24% |
| 2014-12-31 | $5.75 Million | -74.62% |
| 2013-12-31 | $22.66 Million | -24.40% |
| 2012-12-31 | $29.97 Million | -40.54% |
| 2011-12-31 | $50.41 Million | +529.69% |
| 2010-12-31 | $8.01 Million | -55.94% |
| 2009-12-31 | $18.17 Million | +113.88% |
| 2008-12-31 | $8.49 Million | -29.55% |
| 2007-12-31 | $12.06 Million | -- |